HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer

Previously, we have reported a correlation between the expression of HER2/neu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2/neu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infil...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1994-07, Vol.54 (13), p.3387-3390
Main Authors: YOSHINO, I, GOEDEGEBUURE, P. S, PEOPLES, G. E, PARIKH, A. S, DIMAIO, J. M, LYERLY, H. K, GAZDAR, A.F, EBERLEIN, T. J
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - immunology
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - immunology
Female
HLA-A2 Antigen - immunology
Humans
Lung Neoplasms - immunology
Medical sciences
Ovarian Neoplasms - immunology
Pneumology
Proto-Oncogene Proteins - immunology
Receptor, Epidermal Growth Factor - immunology
Receptor, ErbB-2
T-Lymphocytes, Cytotoxic - immunology
Tumor Cells, Cultured
Tumors of the respiratory system and mediastinum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previously, we have reported a correlation between the expression of HER2/neu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2/neu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/neu+ NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neu+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neu+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.
ISSN:0008-5472
1538-7445